Abstract
Background/Aims: Pancreatogenic, or type 3c, diabetes (T3cDM) occurs due to inherited or acquired pancreatic disease or resection. Although similar to the more prevalent type 1 and type 2 diabetes, pancreatogenic diabetes has a unique pattern of hormonal and metabolic characteristics and a high incidence of pancreatic carcinoma in the majority of patients with T3cDM. Despite these differences, no guidelines for therapy have been described. Methods: Published studies on the prevalence, pathophysiology, and cancer associations of T3cDM were reviewed. The recent studies on the protective role and mechanism of metformin therapy as both an anti-diabetic and anti-neoplastic agent were reviewed, and studies on the cancer risk of other anti-diabetic drugs were surveyed. Results: T3cDM accounts for 5–10% of Western diabetic populations and is associated with mild to severe disease. Hepatic insulin resistance is characteristic of T3cDM and is caused by deficiencies of both insulin and pancreatic polypeptide. 75% of T3cDM is due to chronic pancreatitis, which carries a high risk for pancreatic carcinoma. Insulin and insulin secretagogue treatment increases the risk of malignancy, whereas metformin therapy reduces it. Pancreatic exocrine insufficiency associated with T3cDM contributes to nutritional deficiencies and the development of metabolic bone disease. Conclusions: Until consensus recommendations are reached, the glycemic treatment of T3cDM should avoid insulin and insulin secretagogues if possible. Metformin should be the first line of therapy, and continued if insulin treatment must be added for adequate glucose control. Pancreatic enzyme therapy should be added to prevent secondary nutritional and metabolic complications.
References
1.
American Diabetes Association: Diagnosis and classification of diabetes. Diab Care 2011;34(suppl 1):S62–S69.
2.
Centers for Disease Control. National Diabetes Fact Sheet, 2007. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf. Updated 2007. Accessed 1/26/10.
3.
Tiengo A, Alberti KG, Del Prato S, et al: Diabetes secondary to pancreatopathy: new pancreatopathy; in Tiengo A, Alberti KG, Del Prato S, Vranic M (eds): Diabetes Secondary to Pancreatopathy. Proceedings of the Post EASD International Symposium on Diabetes Secondary to Pancreatopathy, Padova, 21–22 September 1987. International Congress Series 762. Amsterdam, Excerpta Medica, 1988, pp 35–50.
4.
Alberti KG: Diabetes secondary to pancreatopathy: an example of brittle diabetes; in Tiengo A, Alberti KG, Del Prato S, Vranic M (eds): Diabetes Secondary to Pancreatopathy. Proceedings of the Post EASD International Symposium on Diabetes Secondary to Pancreatopathy, Padova, 21–22 September 1987, International Congress Series 762. Amsterdam, Excerpta Medica, 1988, pp 211–214.
5.
Ganda O: Secondary forms of diabetes; in Kahn CR, Weir GC (eds): Joslin’s Diabetes Mellitus. New York, Lea & Febiger, 1994.
6.
Abu-Bakare A, Taylor R, Gill GV, et al: Tropical or malnutrition-related diabetes: a real syndrome? Lancet 1986;1:1135–1138.
7.
Mohan V, Pitchumoni C: Tropical chronic pancreatitis; in Beger HG (ed): The Pancreas. London, Blackwell Science, 1998, pp 688–697.
8.
Hardt PD, Kloer HU, Brendel MD, Bretzel RG: Is pancreatic (type 3c) diabetes underdiagnosed and misdiagnosed? Diab Care 2008;31(suppl 2):S165–S169.
9.
Ewald N, Raspe A, Kaufmann C, et al: Determinants of exocrine pancreatic function as measured by fecal elastase-1 concentrations in patients with diabetes mellitus. Eur J Med Res 2009;14:1–6.
10.
Bank S: Chronic pancreatitis: clinical features and medical management. Am J Gastroenterol 1986;81:153–167.
11.
Nyboe Andersen B, Krarup T, Thorsgaard Pedersen NT, et al: B-cell function in patients with chronic pancreatitis and its relation to exocrine pancreatic function. Diabetologia 1982;23:86–89.
12.
Malka D, Hammel P, Sauvanet A, et al: Risk factors for diabetes mellitus in chronic pancreatitis. Gastroenterology 2000;119:1324–1332.
13.
Slezak LA, Andersen DK: Pancreatic resection: effects on glucose metabolism. World J Surg 2001;25:452–460.
14.
Hutchins RR, Hart RS, Pacifico M, Bradley NJ, Williamson RC: Long-term results of distal pancreatectomy for chronic pancreatitis in 90 patients. Ann Surg 2002;236:612–618.
15.
King J, Kazanjian K, Matsumoto J, Reber HA, Yeh MW, Hines OJ, Eibl G: Distal pancreatectomy: incidence of postoperative diabetes. J Gastrointest Surg 2008;12:1548–1553.
16.
Olsen TS: The incidence and clinical relevance of chronic inflammation in the pancreas in autopsy material. Acta Pathol Microbiol Scand A 1978;86:361–364.
17.
Worning H: Alcoholic chronic pancreatitis; in Beger HG (ed): The Pancreas. London, Blackwell Science, 1998, pp 672–679.
18.
Rothenbacher D, Low M, Hardt PD, et al: Prevalence and determinants of exocrine pancreatitic insufficiency among older adults: results of a population-based study. Scand J Gastroenterol 2005;40:697–704.
19.
Cunningham JD, O’Donnell N, Starker P: Surgical outcomes following pancreatic resection at a low-volume community hospital: do all patients need to be sent to a regional cancer center? Am J Surg 2009;198:227–230.
20.
Helm JF, Centeno BA, Coppola D, Druta M, Park JY, Chen DT, Hodul PJ, Kvols LK, Yeatman TJ, Carey LC, Karl RC, Malafa MP: Outcomes following resection of pancreatic adenocarcinoma: 20-year experience at a single institution. Cancer Control 2008;15:288–294.
21.
Moran A, Becker D, Casella SJ, et al: Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes. A technical review. Diab Care 2010;33:2677–2683.
22.
Bliss M: The Discovery of Insulin. Chicago, University of Chicago Press, 1984.
23.
Nosadini R, del Prato S, Tiengo A, et al: Insulin sensitivity, binding, and kinetics in pancreatogenic and type 1 diabetes. Diabetes 1982;31:346–355.
24.
Andres R, Swerdloff R, Pozefsky T, et al: Manual feedback technique for control of glucose concentration; in Skeggs L Jr (ed): Automation in Analytic Chemistry. New York, Medaid Inc, 1966, pp 486–501.
25.
Steele R: Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 1959;82:420–430.
26.
Sun YS, Brunicardi FC, Druck P, et al: Reversal of abnormal glucose metabolism in chronic pancreatitis by administration of pancreatic polypeptide. Am J Surg 1986;151:130–140.
27.
Yeo CJ, Bastidas JA, Schmieg RE Jr, et al: Pancreatic structure and glucose tolerance in a longitudinal study of experimental pancreatitis-induced diabetes. Ann Surg 1989;210:150–158.
28.
Cerosimo E, Pisters PW, Pescola G, et al: Insulin secretion and action in patients with pancreatic cancer. Cancer 1991;67:486–493.
29.
Andersen DK: Mechanisms and emerging treatments of the metabolic complications of chronic pancreatitis. Pancreas 2007;35:1–15.
30.
Kien CL, Horswill CA, Zipf SB, et al: Elevated hepatic glucose production in children with cystic fibrosis. Pediatr Res 1995;37:600–605.
31.
Sive A, Vinik AI, Van Tonder S, Lund A: Impaired pancreatic polypeptide secretion in chronic pancreatitis. J Clin Endocrinol Metab 1978;47:556–559.
32.
Inoue K, Tobe T, Suzuki T, et al: Plasma cholecystokinin and pancreatic polypeptide after radical pancreaticoduodenectomy with Billroth I and Billroth II types of reconstruction. Ann Surg 1986;206:148–154.
33.
Adiran TE, McKiernan J, Johnstone DI, et al: Hormonal abnormalities of the pancreas and gut in cystic fibrosis. Gastroenterology 1980;79:460–465.
34.
Bastidas JA, Couse NF, Yeo CJ, et al: The effect of pancreatic polypeptide infusion on glucose tolerance and insulin response in longitudinally studied pancreatitis-induced diabetes. Surgery 1990;107:661–668.
35.
Seymour NE, Brunicardi FC, Chaiken RL, Lebovitz HE, Chance RE, Gingerich RL, Elahi D, Andersen DK: Reversal of abnormal glucose production after pancreatic resection by pancreatic polypeptide administration in man. Surgery 1988;104:119–129.
36.
Brunicardi FC, Chaiken RL, Ryan AS, et al: Pancreatic polypeptide administration improves abnormal glucose metabolism in patients with chronic pancreatitis. J Clin Endocrinol Metab 1996;81:3566–3572.
37.
Mundlos S, Adler G, Schaar M, et al: Exocrine pancreatic function in oleic acid-induced pancreatic insufficiency in rats. Pancreas 1986;1:29–36.
38.
Seymour NE, Turk JB, Laster MK, et al: In vitro hepatic insulin resistance in chronic pancreatitis in the rat. J Surg Res 1989;46:450–456.
39.
Seymour NE, Andersen DK: Pancreatic polypeptide and glucose metabolism; in Greeley GH (ed): Gastrointestinal Endocrinology. Totowa, Humana Press, 1999, pp 321–334.
40.
Goldstein JA, Kirwin JD, Seymour NE, et al: Reversal of in vitro hepatic insulin resistance in chronic pancreatitis by pancreatic polypeptide in the rat. Surgery 1989;106:1128–1132.
41.
Seymour NE, Volpert AR, Lee EL, et al: Alterations in hepatocyte insulin binding in chronic pancreatitis: effects of pancreatic polypeptide. Am J Surg 1995;169:105–110.
42.
Seymour NE, Spector SA, Andersen DK, et al: Overexpression of hepatic pancreatic polypeptide receptors in chronic pancreatitis. J Surg Res 1998;76:47–52.
43.
Spector SA, Frattini JC, Zdankiewicz PD, et al: Insulin receptor gene expression in chronic pancreatitis: the effect of pancreatic polypeptide. Surg Forum 1997;48:168–171.
44.
Andersen DK, Ruiz CL, Burant CF: Insulin regulation of hepatic glucose transporter protein is impaired in chronic pancreatitis. Ann Surg 1994;219:679–686.
45.
Nathan JD, Zdankiewicz PD, Wang JP, et al: Impaired hepatocyte glucose transport protein (GLUT2) internalization in chronic pancreatitis. Pancreas 2001;22:172–178.
46.
Eisenberg ML, Maker AV, Slezak LA, et al: Insulin receptor and glucose transporter 2 proteins form a complex on the rat hepatocyte membrane. Cell Physiol Biochem 2005;15:51–58.
47.
Seymour NE, Andersen DK: Pancreatic Polypeptide and glucose metabolism; in Greeley GH (ed): Gastrointestinal Endocrinology. Totowa, Humana Press, 1999, pp 321–334.
48.
Kono T, Wang XP, Fisher WE, et al: Pancreatic polypeptide; in Martini L (ed): Encyclopedia of Endocrine Diseases. San Diego, Elsevier, 2004, vol 3, pp 488–496.
49.
Donowitz M, Hendler R, Spiro HM, et al: Glucagon secretion in acute and chronic pancreatitis. Ann Intern Med 1975;83:778–781.
50.
Ebert R, Creutzfeldt WO: Reversal of impaired GIP and insulin secretion in patients with pancreatogenic steatorrhea following enzyme substitution. Diabetologia 1980;19:198–204.
51.
Knop FK, Visboll T, Larsen S, et al: Increased post-prandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution. Am J Physiol Endocrinol Metab 2007;292:E324–E330.
52.
Frey CF, Child CG, Fry W: Pancreatectomy for chronic pancreatitis. Ann Surg 1976;184:403–413.
53.
Gall FP, Muhe E, Gebhardt C: Results of partial and total pancreatectomy in 117 patients with chronic pancreatitis. World J Surg 1981;5:269–275.
54.
Couet C, Genton P, Pointel JP, et al: The prevalence of retinopathy is similar in diabetes mellitus secondary to chronic pancreatitis with or without pancreatectomy and in idiopathic diabetes mellitus. Diab Care 1985;8:323–328.
55.
Aspelund G, Topazian MD, Lee JH, et al: Improved outcomes for benign disease with limited pancreatic head resection. J Gastrointest Surg 2005;9:400–409.
56.
Berstein LM: Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer. Cancer Lett 2005;224:203–212.
57.
Riddle MC, Drucker DJ: Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diab Care 2006;29:435–449.
58.
Masharani U, German MS: Pancreatic hormones and diabetes mellitus; in Gardner DG, Shoback D (eds): Greenspan’s Basic and Clinical Endocrinology (8e: http://www.accessmedicine.com/content.aspx?aID=2633151).
59.
Lebovitz HE: Adjunct therapy for type 1 diabetes mellitus. Nat Rev Endocrinol 2010;6:326–334.
60.
Jemal A, Siegel R, Ward E, et al: Cancer statistics 2007. CA Cancer J Clin 2007;57:43–66.
61.
Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics 2002. CA Cancer J Clin 2005;55:74–108.
62.
Lowenfels AB, Maisonneuve P, Cavallini G, et al: Pancreatitis and the risk of pancreatic cancer. N Engl J Med 1993;328:1433–1437.
63.
Raimondi S, Lowenfels AB, Morselli-Labate AM, Maisonneuve P, Pezzilli R: Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol 2010;24:349–358.
64.
Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, et al: Type 2 diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005;92:2076–2083.
65.
Wideroff L, Gridley G, Mellemkjaer L, et al: Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997;89:1360–1365.
66.
Calle EE, Rodriguez C, Walker-Thurmond K, et al: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003;348:1625–1638.
67.
Magruder JT, Elahi D, Andersen DK: Diabetes and pancreatic cancer: chicken or egg? Pancreas 2011;40:339–351.
68.
Inoue M, Iwasaki M, Otani T, et al: Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006;166:1871–1877.
69.
Saydah SH, Platz EA, Rifai N, et al: Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarker Prevent 2003;12:412–418.
70.
Batty GD, Shipley MJ, Marmot M, et al: Diabetes status and post-load plasma glucose concentration in relation to site-specific cancer mortality: findings from the original Whitehall study. Cancer Causes Control 2004;15:873–881.
71.
Jee SH, Ohrr H, Sull JW, et al: Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005;293:194–202.
72.
Stolzenberg-Solomon RZ, Graubard BI, Chari S, et al: Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 2005;294:2872–2878.
73.
Butler AE, Galasso R, Matveyenko A, et al: Pancreatic duct replication is increased with obesity and type 2 diabetes in humans. Diabetologia 2010;53:21–26.
74.
Pollak M: Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer 2008;8:915–928.
75.
Rozengurt E, Sinnett-Smith J, Kisfalvi K: Crosstalk between insulin/insulin-like growth factor-1 receptors and G-protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res 2010;16:2505–2511.
76.
Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A, Vigneri R: The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 2008;114:23–37.
77.
Belfiore A: The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 2007;13:671–686.
78.
Azar M, Lyons TJ: Diabetes, insulin treatment, and cancer risk: what is the evidence? F1000 Med Rep 2010;2(pii):4.
79.
Ding XZ, Fehsenfeld DM, Murphy LO, et al: Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression. Pancreas 2000;21:310–320.
80.
Bonelli L, Aste H, Bovo P, et al: Exocrine pancreatic cancer, cigarette smoking, and diabetes mellitus: a case-control study in northern Italy. Pancreas 2003;27:143–149.
81.
Bowker SL, Majumdar SR, Veugelers P, et al: Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diab Care 2006;29:254–258.
82.
Maisonneuve P, Lowenfels AB, Bueno-de-Mesquita HB, et al: Past medical history and pancreatic cancer risk: results from a multicenter case-control study. Ann Epidemiol 2010;20:92–98.
83.
Evans JM, Donnelly LA, Emslie-Smith AM, et al: Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304–1305.
84.
Libby G, Donnelly LA, Donnan PT, et al: New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diab Care 2009;32:1620–1625.
85.
Li D, Yeung SC, Hassan MM, et al: Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009;137:482–488.
86.
Schneider MB, Matsuzaki H, Haorah J, et al: Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 2001;120:1263–1270.
87.
Shaw RJ, Lamia KA, Vasquez D, et al: The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005;310:1642–1646.
88.
Zakikhani M, Dowling R, Fantus IG, et al: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269–10273.
89.
Kisfalvi K, Eibl G, Sinnett-Smith J, et al: Metformin disrupts crosstalk between G-protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 2009;69:6539–6545.
90.
Shaw RJ, Bardeesy N, Manning BD, et al: The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004;6:91–99.
91.
Alessi DR, Sakamoto K, Bayascas JR: LKB1-dependent signaling pathways. Annu Rev Biochem 2006;75:137–163.
92.
Rozengurt E: Mitogenic signaling pathways induced by G-protein-coupled receptors. J Cell Physiol 2007;213:589–602.
93.
Dowling RJ, Zakikhani M, Fantus IG, et al: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007;67:10804–10812.
94.
Gotlieb WH, Saumet J, Beauchamp MC, et al: In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 2008;110:246–250.
95.
Jiralerspong S, Palla SL, Giordano SH, et al: Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009;27:3297–3302.
96.
Maida A, Lamont BJ, Cao X, Drucker DJ: Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice. Diabetologia 2011;54:339–349.
97.
Stoffers DA, Kieffer TJ, Hussain MA, et al: Insulinotropic glucagon-like peptide-1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000;49:741–748.
98.
Matveyenko AV, Dry S, Cox HI, et al: Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 2009;58:1604–1615.
99.
Moran A, Brunzell C, Cohen RC, et al: Clinical care guidelines for cystic fibrosis-related diabetes. Diab Care 2010;33:2697–2708.
100.
Kirk D, Buse JB: Clinical care guidelines: too much of a good thing? Diab Care 2010;33:2716–2717.
101.
American Diabetes Association: Standards of medical care in diabetes – 2011. Diab Care 2011;34(suppl 1):S11–S61.
102.
DeWitt DE, Hirsch IB: Outpatient insulin therapy in type 1 and type 2 diabetes mellitus. JAMA 2003;289:2254–2264.
103.
Mooradian AD, Bernbaum M, Albert SG: Narrative review: a rational approach to starting insulin therapy. Ann Intern Med 2006;145:125–134.
104.
Nathan DM, Holman RR, Buse JB, et al: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diab Care 2009;32:193–203.
105.
Diabetes Control and Complications Trial Research Group: The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes: The Diabetes Control and Complications Trial. N Engl J Med 1993;329:978–986.
106.
UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853.
107.
UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–865.
108.
Lund SS, Tarnow L, Astrup AS, et al: Effect of adjuvant metformin treatment in patients with type 1 diabetes and persistent inadequate glycemic control. A randomized study. PLoS ONE 2008;3(10):e3363.
109.
Riccardi G, Giacco R, Parillo M, et al: Efficacy and safety of acerbose in the treatment of type 1 diabetes mellitus: a placebo-controlled, double-blind, multicentre study. Diabet Med 1999;16:228–232.
110.
Rabiee A, Galiatsatos P, Salas-Carrillo R, et al: Pancreatic polypeptide infusion increases insulin sensitivity and reduces the insulin requirement of patients on insulin pump therapy. J Diab Sci Technol 2011 (in press).
111.
Hardt PD, Hauenschild A, Nalop J, et al: High prevalence of exocrine pancreatic insufficiency in diabetes mellitus: a multicenter study screening fecal elastase-1 concentrations in 1,021 diabetic patients. Pancreatology 2003;3:395–403.
112.
Mann, ST, Stracke H, Lange U, et al: Alterations in bone mineral density and bone metabolism in patients with various grades of chronic pancreatitis. Metabolism 2003;52:579–585.
113.
Loser C, Mollgaard A, Folsch UR: Faecal elastase-1: a novel, highly sensitive, and specific tubeless pancreatic function test. Gut 1996;39:580–586.
114.
Domínguez-Muñoz JE, Iglesias-García J, Vilariño-Insua M, et al: 13C-mixed triglyceride breath test to assess oral enzyme substitution therapy in patients with chronic pancreatitis. Clin Gastroenterol Hepatol 2007;5:484–488.
© 2011 S. Karger AG, Basel and IAP
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
